Version: August 2022
Nonclinical Characterization of Bexmarilimab, a Clever-1–Targeting Antibody for Supporting Immune
Maija Hollmén1,2, Mikael Maksimow1,3, Jenna H. Rannikko1,2, Matti K. Karvonen3, Marita Vainio3, Sirpa Jalkanen1,2, Markku Jalkanen3, and Jami Mandelin3
1MediCity Research Laboratory, Faculty of Medicine, University of Turku, Turku, Finland
2InFLAMES Flagship, University of Turku, Turku, Finland
3Faron Pharmaceuticals, Turku, Finland
Mol Cancer Ther 2022; 1207-18. doi: 10.1158/1535-7163.MCT- 21-0840
A Phase I Pharmacokinetic Study of Copanlisib in Chinese Patients with Relapsed Indolent Non-Hodgkin Lymphoma
Weiping Liu1, Lingyan Ping1, Yan Xie1, Yingli Sun1, Tingting Du1, Yi Niu2, Galia Cisternas3, Funan Huang4, Jose Garcia-Vargas4, Barrett H Childs4, Aruna Mehra4, Susanne Reschke3, Xiaopei Wang1, Yuqin Song5 , Jun Zhu6
1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, No.52 Fucheng Road, Haidian District, Beijing, 100142, China
2Bayer HealthCare Co. Ltd., Beijing, China
3Bayer AG, Berlin, Germany
4Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA
5Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, No.52 Fucheng Road, Haidian District, Beijing, 100142, China
6Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, No.52 Fucheng Road, Haidian District, Beijing, 100142, China
Cancer Chemother Pharmacol 2022; Mar 23. doi: 10.1007/s00280-022-04417-3
A Small Molecule–Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an αVß3 Binder for the Treatment of Multiple Cancer Types
Hans-Georg Lerchen1, Beatrix Stelte-Ludwig1, Charlotte Kopitz2, Melanie Heroult3, Dmitry Zubov4, Joerg Willuda5, Thomas Schlange4, Antje Kahnert4, Harvey Wong6, Raquel Izumi6 and Ahmed Hamdy6
1Vincerx Pharma GmbH, 40789 Monheim am Rhein, Germany
2Nuvisan Innovation Campus, 13353 Berlin, Germany
3Crop Science Division, Bayer AG, 65926 Frankfurt am Main, Germany
4Pharmaceuticals R&D, Bayer AG, 42096 Wuppertal, Germany
5Pharmaceuticals R&D, Bayer AG, 13353 Berlin, Germany
6Vincerx Pharma Inc., Palo Alto, CA 94306, USA
Cancers 2022; 14(2), 391. doi: 10.3390/cancers14020391
T cell-Mediated Elimination of Cancer Cells by Blocking CEACAM6-CEACAM1 Interaction
Jessica Pinkerta , Hans-Henning Boehma , Mark Trautweinb , Wolf-Dietrich Doeckec , Florian Wessela , Yingzi Gea , Eva Maria Gutierreza , Rafael Carreteroa , Christoph Freibergb , Uwe Gritzand , Merlin Luetke-Everslohc , Sven Golfierc , Oliver Von Ahsenc , Valentina Volpine , Antonio Sorrentinoe , Anchana Rathinasamye , Maria Xydiae , Robert Lohmayere ,f , Julian Saxe , Ayse Nur-Menevsee , Abir Husseine , Slava Stamovae , Georg Beckmannc , Julian Marius Glueckb , Dorian Schoenfeldb , Joerg Weiskec , Dieter Zopfc , Rienk Offringaa ,g , Bertolt Kreftc , Philipp Beckhovea ,e ,h ,* , and Joerg Willudac, *
a Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany
b Pharmaceutical Division, Bayer AG, Wuppertal, Germany
c Pharmaceutical Division, Bayer AG, Berlin, Germany
d Pharmaceutical Division, Bayer AG, Cologne, Germany
e Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, Germany
f Institute of Theoretical Physics, University of Regensburg, Regensburg, Germany
g Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
h Hematology and Oncology Department, University Hospital Regensburg, Regensburg, Germany
Oncoimmunology 2022; 11(1):2008110. doi: 10.1080/2162402X.2021.2008110
Immunostimulatory Effects of Targeted Thorium-227 Conjugates as Single Agent and in Combination with Anti-PD-L1 Therapy
Pascale Lejeune1, Véronique Cruciani2, Axel Berg-Larsen2, Andreas Schlicker1, Anne Mobergslien2, Lisa Bartnitzky1, Sandra Berndt1, Sabine Zitzmann-Kolbe1, Claudia Kamfenkel1, Stefan Stargard1, Stefanie Hammer1, Jennifer S Jørgensen3, Malene Jackerott3, Carsten H Nielsen3, Christoph A Schatz1, Hartwig Hennekes1, Jenny Karlsson2, Alan S Cuthbertson2, Dominik Mumberg1, Urs B Hagemann4
1Bayer AG, Berlin, Germany; 2Bayer AS, Oslo, Norway; 3Minerva Imaging ApS, Copenhagen, Denmark; 4Bayer AG, Berlin, Germany
J Immunother Cancer 2021; 9(10):e002387. doi: 10.1136/jitc-2021-002387
Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models
Stefanie Hammer1 , Andreas Schlicker1 , Sabine Zitzmann-Kolbe1 , Simon Baumgart2 , Urs B Hagemann1 , Arne Scholz1 , Bernard Haendler1 , Pascale Lejeune1 , Jenny Karlsson3 , Christine Ellingsen3 , Hartwig Hennekes1 , Carsten H Nielsen4 , Mark U Juul4 , Dominik Mumberg1 , Christoph A Schatz5
1Bayer AG, Berlin, Germany; 2Bayer U.S. LLC, Pharmaceuticals, Cambridge, Massachusetts, USA; 3Bayer AS, Oslo, Norway; 4Minerva Imaging, Copenhagen, Denmark; 5Bayer AG, Berlin, Germany, christoph.schatz@bayer.com.
Clin Cancer Res 2021; 27 (15), 4367-4378. doi: 10.1158/1078-0432.CCR-21-0342 https://clincancerres.aacrjournals.org/content/27/15/4367
Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model
Mari I. Suominen 1, Jenni Mäki-Jouppila 1, Anna Huhtinen 2, Birgitta Sjöholm 2, Jukka P. Rissanen 1, Anniina Luostarinen 1, Katja M. Fagerlund 1, Esa Alhoniemi 3, Gerhard Siemeister 4, Dominik Mumberg 5, Sanna-Maria Käkönen 2,6 and Arne Scholz 5,*
1 Pharmatest Services Oy, 20520 Turku, Finland; 2 Aurexel Life Sciences Oy, 21240 Askainen, Finland; 3 Vincit Oyj, 20500 Turku, Finland; 4 Nuvisan-ICB GmbH, Therapeutic Oncology Research, 13353 Berlin, Germany; 5 Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany; 6 Department of Cell Biology and Anatomy, Faculty of Medicine, University of Turku, 20014 Turku, Finland
Int J Mol Sci 2021; 22, 5570. doi: 10.3390/ijms22115570
Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors
Antje Wick1 , Oliver Bähr2, Martin Schuler3, Kristoffer Staal Rohrberg4, Sant P Chawla5, Janku Filip6, David Schiff 7, Volker Heinemann8, Yoshitaka Narita9, Heinz-Josef Lenz10, Masafumi Ikeda11, Yuichi Ando12, Wolfgang Wick13, Joachim P Steinbach14, Michael C Burger14, Katharina J Wenger15, Ulrik Lassen16, Kamalesh K Sankhala17, Cristiana M Roggia18, Isabelle Genvresse19, Catya Munhoz20, Christine Rentzsch21, Susanne Reschke19, Simon Langer22, Markus Wagner21, Stefan Kaulfuss23, Charles Cai24, Eleni Lagkadinou21, Michael Jeffers25, Carol Pena26, Ghazaleh Tabatabai27
1 Neurology, University Hospital Heidelberg; 2 Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt; 3 Department of Medical Oncology, University Hospital Essen; 4 Department of Oncology, Copenhagen University Hospital, Rigshospitalet; 5 N/A, Sarcoma Oncology Center; 6 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center; 7 Neurology, University of Virginia; 8 Department of Medical Oncology and Comprehensive Cancer Center, University of Munich; 9 Department of Neurosurgery and Neuo-Oncology, National Cancer Center Central Hospital; 10 Medicine, Norris Comprehensive Cancer Center, University of Southern California; 11 Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East; 12 Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital; 13 German Cancer Consortium (DKTK); 14 Dr. Senckenberg Institute of Neurooncology, Goethe University Hospital; 15 Institute of Neuroradiology, University Hospital Frankfurt, Frankfurt am Main; 16 Oncology, The Finsen Centre, Rigshospitalet; 17 Sarcoma Oncology Center; 18 Institute of Medical Genetics and Applied Genomics, University Hospital of Tuebingen; 19 Pharmaceuticals Division, Bayer AG; 20 Bayer HealthCare; 21 Bayer AG; 22 Statistics, Chrestos Concept GmbH & Co. KG; 23Research & Development, Bayer AG; 24 Bayer HealthCare Pharmaceuticals, Inc; 25 Clinical Sciences, Bayer Healthcare Pharmaceuticals; 26Global Biomarkers, Bayer HealthCare Pharmaceuticals, Inc; 27 Neurology & Neurooncology, Eberhard Karls University & University Hospital Tuebingen.
Clin Cancer Res 2021; 27(10):2723-2733. doi: 10.1158/1078-0432.CCR-20-4256
IL3RA-Targeting Antibody–Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic Malignancies
Dennis Kirchhoff 1, Beatrix Stelte-Ludwig 2, Hans-Georg Lerchen 2, Antje Margret Wengner 1, Oliver von Ahsen 1, Pascale Buchmann 2, Stephan Märsch 2, Christoph Mahlert 2, Simone Greven 2, Lisa Dietz 2, Michael Erkelenz 1, Ruprecht Zierz 1, Sandra Johanssen 1, Dominik Mumberg 1 and Anette Sommer 1
1 Bayer AG, Pharmaceuticals, Research & Development, 13342 Berlin, Germany; 2 Bayer AG, Pharmaceuticals, Research & Development, 42096 Wuppertal, Germany
Cancers 2020; 12(11), 3464. doi: 10.3390/cancers12113464
Combination of Copanlisib With Cetuximab Improves Tumor Response in Cetuximab-resistant Patient-derived Xenografts of Head and Neck Cancer
Konrad Klinghammer1, Oliver Politz2, Theresa Eder3,4, Raik Otto5, Jan-Dirk Raguse6, Andreas Albers7, Andreas Kaufmann8, Jens Hoffmann9, Ulrich Keller1 and Ulrich Keilholz10
1,3,7,8,10Charité, Berlin, Germany; 2Bayer AG, Berlin, Germany; 4German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) Partner Sites, Berlin, Germany; 5Humboldt-Universität zu Berlin, Germany; 6Fachklinik Hornheide, Münster, Germany; 9Experimental Pharmacology & Oncology GmbH, Berlin, Germany
Oncotarget 2020; 11(41):3688-3697. doi: 10.18632/oncotarget.27763
Safety and Efficacy of BAY1436032 in IDH1-mutant AML: Phase I Study Results
Michael Heuser1, Neil Palmisiano2, Ioannis Mantzaris3, Alice Mims4, Courtney DiNardo5, Lewis R. Silverman6, Eunice S. Wang7, Walter Fiedler8, Claudia Baldus9, Sebastian Schwind10, Timothy Pardee11, Alexander E. Perl12, Charles Cai13, Stefan Kaulfuss14, Eleni Lagkadinou14, Christine Rentzsch14, Markus Wagner14, Gary Wilkinson14, Bingyan Wu13, Michael Jeffers13, Isabelle Genvresse14, Alwin Krämer15
1Hannover Medical School, Hannover, Germany; 2Thomas Jefferson University, Philadelphia, PA, USA; 3Albert Einstein College of Medicine, Bronx, NY, USA; 4The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; 5 M.D. Anderson Cancer Center, Houston, TX, USA; 6Tisch Cancer Institute, New York, NY, USA; 7Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; 8University Hospital Hamburg-Eppendorf, Hamburg, Germany; 9Charité University Hospital Berlin, Berlin, Germany; 10 University Hospital Leipzig, Leipzig, Germany; 11Hematology and Oncology Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC, USA; 12Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA; 13Bayer HealthCare Pharmaceuticals, Inc., Whippany, USA; 14Bayer AG, Berlin, Germany; 15German Cancer Research Center (DKFZ) and University of Heidelberg, Heidelberg, Germany
Leukemia 2020; 34(11):2903-2913. doi: 10.1038/s41375-020-0996-5
Tailored Linker chemistries for the Efficient and Selective Activation of ADCs with KSPi Payloads
Hans-Georg Lerchen*, Beatrix Stelte-Ludwig, Anette Sommer, Sandra Berndt, Anne-Sophie Rebstock, Sarah Johannes, Christoph Mahlert, Simone Greven, Lisa Dietz, and Hannah Jörißen
Bayer AG, Berlin, Germany
Bioconjugate Chem 2020; 31:1893-1898. doi: 10.1021/acs.bioconjchem.0c00357
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2)
Julia Huetter1, Uwe Gritzan2, Ilona Gutcher1, Wolf-Dietrich Doecke3, Merlin V. Luetke-Eversloh4, Sven Golfier4, Helge G. Roider5, Anna-Lena Frisk1, John Hunter6, Andrew Pow7, Andrew Drake6, Zurit Levine8, Ofer Levy8, Meir Azulay8, Inbal Barbiro8, Gady Cojocaru8, Ilan Vaknin8, Bertolt Kreft1, and Lars Roese1
1,3-5Bayer AG, Berlin, Germany; 2Bayer AG, Cologne, Germany; 6Compugen USA Inc., San Francisco, CA; 7New Paradigm Biosciences, Woburn, MA; 8Compugen Ltd., Holon, Israel.
Cancer Immunol Res 2020; 8:895-911. doi: 10.1158/2326-6066.CIR-19-0321; PMID: 32312711
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-inducing or Repair-compromising Therapies in Preclinical Cancer Models
Antje Margret Wengner1, Gerhard Siemeister1, Ulrich Lücking1, Julien Lefranc1, Lars Wortmann1, Philip Lienau1, Benjamin Bader1, Ulf Bömer1, Dieter Moosmayer1, Uwe Eberspächer1, Sven Golfier1, Christoph Schatz1, Simon J. Baumgart1, Bernard Haendler1, Pascale Lejeune1, Andreas Schlicker1, Franz von Nussbaum1, Michael Brands1, Karl Ziegelbauer1 and Dominik Mumberg1
1 Bayer AG, Pharmaceuticals, Research & Development, Berlin, Germany.
Mol Cancer Ther 2020; 19(1):26-38. doi: 10.1158/1535-7163.MCT-19-0019 https://aacrjournals.org/mct/article/19/1/26/92777/The-Novel-ATR-Inhibitor-BAY-1895344-Is-Efficacious
Preclinical Efficacy of a PSMA-targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
Hammer S1, Hagemann UB2, Zitzmann-Kolbe S1, Larsen A2, Ellingsen C2, Geraudie S2, Grant D2, Indrevoll B2, Smeets R2, von Ahsen O1, Kristian A2, Lejeune P1, Hennekes H1, Karlsson J2, Bjerke RM2, Ryan OB2, Cuthbertson AS2, Mumberg D1
1Bayer AG, Berlin, Germany; 2Bayer AS, Oslo, Norway.
Clin Cancer Res 2020; 26(8):1985-1996. doi: 10.1158/1078-0432.CCR-19-2268.
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy
Schneeweiss A1, Hess D2, Joerger M2, Varga A3, Moulder S4, Tsimberidou AM4, Ma C5, Hurvitz SA6, Rentzsch C7, Rudolph M7, Thiele S7, Boix O7, Wilkinson G7, Lagkadinou E7, Ocker M7
1 National Center for Tumor Diseases, University Hospital Heidelberg and German Cancer Research Center, Germany; 2Kantonsspital St. Gallen, Switzerland; 3Institut Gustave Roussy, Villejuif, France; 4MD Anderson Cancer Center, Houston, TX, USA; 5Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA; 6David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA;7Bayer AG, Berlin, Germany.
Cancers (Basel) 2019; 11(12). pii: E1987. doi: 10.3390/cancers11121987
The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis
Suominen MI1, Wilson T2, Käkönen S-M2,3, Scholz A4
1Pharmatest Services Ltd., Turku, Finland; 2Aurexel Life Sciences Ltd., Askainen, Finland; 3Institute of Biomedicine, Faculty of Medicine, University of Turku, Finland; 4Bayer AG, Berlin, Germany.
Int J Mol Sci. 2019; 20(16):3899. pii: E3899. doi: 10.3390/ijms20163899.
Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): Preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers
Hagemann UB1, Ellingsen C1, Schuhmacher J2, Kristian A1, Mobergslien A1, Cruciani V1, Wickstroem K1, Schatz CA2, Kneip C2, Golfier S2, Smeets R1, Uran SR1, Hennekes H1, Karlsson J2, Bjerke RM1, Ryan OB1, Mumberg D2, Ziegelbauer K2, Cuthbertson AS1
1Bayer AS, Norway; 2Bayer AG, Germany.
Clin Cancer Res 2019; 25(15):4723-4734. doi: 10.1158/1078-0432.CCR-18-3476
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models
Grünewald S1, Politz O1, Bender S1, Héroult M1, Lustig K2, Thuss U2, Kneip C1, Kopitz C1, Zopf D1, Collin MP2, Boemer U1, Ince S3, Ellinghaus P2, Mumberg D1, Hess-Stumpp H1, Ziegelbauer K2
1Bayer AG, Berlin, Germany; 2Bayer AG, Wuppertal, Germany; 3Bayer U.S. LLC, Whippany, NJ.
Int J Cancer 2019; 145(5):1346-1357. doi: 10.1002/ijc.32224
Sequential treatment with doxorubicin and zoledronic acid has no additive effects in an aggressive model of established bone metastases
Mari I. Suominen1, Rami Käkönen2, Jukka P. Rissanen3, Jussi M. Halleen1, Pirkko Härkönen4, Sanna-Maria Käkönen2,4
1Pharmatest Services Ltd., Turku, Finland; 2Aurexel Life Sciences Ltd., Askainen, Finland; 3PreclinApps Ltd., Raisio, Finland; 4Institute of Biomedicine, University of Turku, Turku, Finland.
J Cancer Metastasis Treat 2019; 5:14. doi: 10.20517/2394-4722.2018.64
Anetumab Ravtansine Inhibits Tumor Growth and Shows Additive Effect in Combination with Targeted Agents and Chemotherapy in Mesothelin-expressing Human Ovarian Cancer Models
Maria Quanz1, Urs B. Hagemann1, Sabine Zitzmann-Kolbe1, Beatrix Stelte-Ludwig2, Sven Golfier1, Cem Elbi3, Dominik Mumberg1, Karl Ziegelbauer1 and Christoph A. Schatz1
1Bayer AG, Berlin, Germany, 2Bayer AG, Wuppertal, Germany, 3Bayer US LLS
Oncotarget 2018; 9(75):34103-34121. doi: 10.18632/oncotarget.26135
ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer
Katriina J. Peltolaa, Petri Bonoa, Robert Hugh Jonesb, Egils Vjatersc, Pirjo Nykänend, Annamari Vuorelad, Riikka Oksalad, Pasi Pohjanjousid, Mika V.J. Mustonend,, Karim Fizazie, Christophe Massardf
aHelsinki University Hospital, Comprehensive Cancer Centre, Helsinki, Finland; bVelindre Cancer Centre, Cardiff, UK; cP. Stradins Clinical University Hospital, Riga, Latvia; dOrion Corporation Orion Pharma, Espoo, Finland; eInstitut Gustave-Roussy, University of Paris Sud, Villejuif, France; fUniversité Paris Saclay, Université Paris-Sud, Gustave Roussy, Villejuif, France
European Urology Focus 2020; 6(1):63-70. doi: 10.1016/j.euf.2018.08.022
Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models
Mari I. Suominen1, Katja M. Fagerlund1, Jukka P. Rissanen1, Yvonne M. Konkol1, Jukka P. Morko1, ZhiQi Peng1, Esa J. Alhoniemi2, Salla K. Laine3, Eva Corey4, Dominik Mumberg5, Karl Ziegelbauer5, Sanna-Maria Käkönen3,6, Jussi M. Halleen1, Robert L. Vessella4, Arne Scholz5
1 Pharmatest Services Ltd, Turku, Finland; 2 Avoltus Oy, Turku, Finland; 3Aurexel Life Sciences Ltd, Askainen, Finland; 4University of Washington, Seattle, USA; 5Bayer AG, Berlin, Germany; 6University of Turku, Finland
Clin Cancer Res 2017; 23(15):4335-4346. PMID: 28364014
Preclinical Anti-Tumor Efficacy of BAY 1129980 – a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer
Jörg Willuda1, Lars Linden2, Hans-Georg Lerchen2, Charlotte Kopitz1, Beatrix Stelte-Ludwig2, Carol Pena3, Claudia Lange1, Sven Golfier1, Christoph Kneip1, Patricia E. Carrigan1, Kirk Mclean4, Joachim Schuhmacher2, Oliver von Ahsen1, Jörg Müller1, Frank Dittmer2, Rudolf Beier1, Sherif El-Sheikh2, Jan Tebbe2, Gabriele Leder1, Heiner Apeler2, Rolf Jautelat2, Karl Ziegelbauer2, Bertolt Kreft1
1Bayer AG, Berlin, Germany; 2Bayer AG, Wuppertal, Germany; 3Bayer LLC, Whippany, NJ, USA; 4Bayer LLC, Mission Bay, San Francisco, CA, USA.
Mol Cancer Ther 2017; 16(5):893-904. PMID: 28292941
Acetyl-CoA Carboxylase Inhibitors Attenuate WNT and Hedgehog Signaling and Suppress Pancreatic Tumor Growth
Elissaveta Petrova1, Arne Scholz1, Juliane Paul1, Andrea Sturz1, Katja Haike1, Franziska Siegel1, Dominik Mumberg1, and Ningshu Liu1
1 Bayer AG, Drug Discovery, Berlin, Germany
Oncotarget 2017; 8(30):48660-48670. PMID: 27750213
BAY 1143269, a Novel MNK1 Inhibitor, Targets Oncogenic Protein Expression and Shows Potent Anti-Tumor Activity
Susann Santag, Franziska Siegel, Antje M. Wengner, Claudia Lange, Ulf Bömer, Knut Eis, Florian Pühler, Philip Lienau, Linda Bergemann, Martin Michels, Franz von Nussbaum 3, Dominik Mumberg, Kirstin Petersen
Bayer AG, Drug Discovery, Pharmaceuticals, Berlin, Germany
Cancer Lett 2017; 390:21-29. PMID: 28043914
Simultaneous Inhibition of PI3Kδ and PI3Ka Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-kB and AKT
Juliane Paul1, Maurice Soujon1, Antje M. Wengner1, Sabine Zitzmann-Kolbe1, Andrea Sturz1, Katja Haike1, Koh Hui Keng Magdalene2, Sze Huey Tan3, Martin Lange1, Soo Yong Tan2, Dominik Mumberg1, Soon Thye Lim4, Karl Ziegelbauer1, and Ningshu Liu1
1Bayer AG, Drug Discovery Oncology, Berlin, Germany, 2Advanced Molecular Pathology Laboratory, Singapore Health Services Pte Ltd, Singapore, Singapore, 3Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, Singapore, Singapore, 4Office of Education, Duke-NUS Graduate Medical School, Singapore, Singapore
Cancer Cell 2017; 31(1):64-78. PMID: 28073005
BAY 1125976, a Selective Allosteric AKT1/2 Inhibitor, Exhibits High Efficacy n AKT Signaling-Dependent Tumor Growth in Mouse Models
Oliver Politz1, Franziska Siegel1, Lars Bärfacker2, Ulf Bömer1, Andrea Hägebarth1, William J. Scott3, Martin Michels2, Stuart Ince3, Roland Neuhaus1, Kirstin Meyer1, Amaury Ernesto Fernández-Montalván1, Ningshu Liu1, Franz von Nussbaum4, Dominik Mumberg1, and Karl Ziegelbauer1
1 Bayer AG, Berlin, Germany, 2 Bayer AG, Wuppertal, Germany, 3 Bayer HealthCare, 4 Bayer S.A.S., France
Int J Cancer 2017; 140(2):449-459. PMID: 27699769
Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors
Anette Sommer1, Charlotte Kopitz1, Christoph A. Schatz1, Carl F. Nising2, Christoph Mahlert2, Hans-Georg Lerchen2, Beatrix Stelte-Ludwig2, Stefanie Hammer1, Simone Greven2, Joachim Schuhmacher2, Manuela Braun1, Ruprecht Zierz1, Sabine Wittemer-Rump1,Axel Harrenga3, Frank Dittmer2, Frank Reetz1, Heiner Apeler2, Rolf Jautelat2, Hung Huynh4, Karl Ziegelbauer1, and Bertolt Kreft1
1 Bayer Pharma AG, Berlin, Germany, 2 Bayer Pharma AG, Wuppertal, Germany, 3 Bayer Intellectual Property GmbH, Monheim, Germany, 4 National Cancer Center Singapore, Division of Cellular & Molecular Research, Singapore.
Cancer Res 2016; 76(21):6331-6339. PMID: 27543601
RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
Peter Brünker1, Katharina Wartha2, Thomas Friess2, Sandra Grau-Richards1, Inja Waldhauer1, Claudia Ferrara Koller1, Barbara Weiser2, Meher Majety2, Valeria Runza2, Huifeng Niu3, Kathryn Packman3, Ningping Feng3, Sherif Daouti3, Ralf J. Hosse1, Ekkehard Mössner1, Thomas G. Weber2, Frank Herting2, Werner Scheuer2, Hadassah Sade2, Cuiying Shao4, Bin Liu4, Peng Wang4, Gary Xu4, Suzana Vega-Harring2, Christian Klein1, Klaus Bosslet2, and Pablo Umaña1
1 Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland, 2 Roche Innovation Center Munich, Penzberg, Germany, 3 Roche Innovation Center New York, US, 4 Roche Innovation Center Shanghai, China
Mol Cancer Ther 2016; 15(5):1-12. PMID: 27037412
Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
Sven Golfier, Charlotte Kopitz, Antje Kahnert, Iring Heisler, Christoph A. Schatz, Beatrix Stelte-Ludwig, Anke Mayer-Bartschmid, Kerstin Unterschemmann, Sandra Bruder, Lars Linden, Axel Harrenga, Peter Hauff, Frank-Detlef Scholle, Beate Müller-Tiemann, Bertolt Kreft, and Karl Ziegelbauer
Bayer HealthCare Pharmaceuticals, Berlin/Wuppertal, Germany
Mol Cancer Ther 2014; 13(6):1537-1548. PMID: 24714131
In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548
Esa Kähkönen1, Ivan Jambor5,6, Jukka Kemppainen2,5, Kaisa Lehtiö3, Tove J. Grönroos5, Anna Kuisma3, Pauliina Luoto5, Henri J. Sipilä5, Tuula Tolvanen5, Kalle Alanen4, Jonna Silén5, Markku Kallajoki4, Anne Roivainen5, Niklaus Schäfer7,8, Roger Schibli9, Martina Dragic9, Anass Johayem8, Ray Valencia10, Sandra Borkowski10, and Heikki Minn3,5
1 Department of Surgery, Division of Urology, Departments of 2 Clinical Physiology and Nuclear Medicine, 3 Oncology and Radio- therapy, and 4 Pathology, Turku University Hospital; 5 Turku PET Centre; 6 Department of Diagnostic Radiology, University of Turku, Turku, Finland; Departments of 7 Medical Oncology and 8 Nuclear Medicine, University Hospital of Zurich; 9 Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland; 10 Bayer Pharma AG, Berlin, Germany
Clin Cancer Res 2013; 19(19):5434-5443. PMID: 23935037
Survival Benefit with Radium-223 Dichloride in a Mouse Model of Breast Cancer Bone Metastasis
Mari I. Suominen1, Jukka P. Rissanen1, Rami Käkönen1, Katja M. Fagerlund1, Esa Alhoniemi1, Dominik Mumberg2, Karl Ziegelbauer2, Jussi M. Halleen1, Sanna-Maria Käkönen3, and Arne Scholz2
1 Pharmatest Services Ltd, Turku, Finland; 2 GlobalDrugDiscovery, Bayer HealthCare, Berlin, Germany; 3 Department of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Finland
J Natl Cancer Inst 2013; 105:908–916. PMID: 23682134